MEP Warns: Big Tech Could Outpace Healthcare Regulation

An unnamed Member of the European Parliament has issued a warning regarding the rapid acceleration of healthcare transformation by major technology companies, especially in drug development. The MEP highlighted that advancements via artificial intelligence (AI) and biofoundries could outpace existing regulatory frameworks, necessitating a proactive policy response.

The pharmaceutical sector already leverages AI to streamline drug discovery, aiming to reduce the typical 10-14 year development cycle and $2.6 billion cost per new drug. Projects like AIIPDD are developing AI-driven intelligence engines specifically for this purpose. Such technologies identify thousands of new molecules, dramatically shortening the initial phases of drug development.

This technological shift underscores the critical role of AI in informing regulatory decision-making. The Real4Reg project, for example, is dedicated to developing, optimising, and implementing AI methods for real-world data analyses in regulatory and health technology assessment across the product lifecycle. Its objective is to enable and establish the value of real-world evidence derived from real-world data (RWD) in assessing medicinal products. The project aims to inform training activities and implement findings in existing and emerging guidelines for health regulatory authorities and health technology assessment bodies across Europe.

However, the proliferation of AI in high-impact societal applications such as biomedicine and healthcare also brings regulatory challenges. Europe is actively pushing to regulate AI, particularly to ensure responsible implementation. The AHEAD project is building a transdisciplinary community to address these issues, focusing on creating standardised approaches for responsible AI. It draws expertise from biomedicine, ethics, AI development, law, and other fields to evaluate AI applications and datasets, ensuring ethical and legal compliance in health.

What this means: Policymakers must move swiftly to create adaptable regulatory frameworks that can keep pace with technological innovation, ensuring patient safety and ethical standards while harnessing AI's potential in healthcare.